ONCOMATRYX said in an announcement from Derio, Spain that it has raised $67 million to support the clinical development of its Quantum antibody‑drug conjugates, or Quantum ADCs, targeting the tumor microenvironment.
The financing round was led by the company’s institutional backers and includes $28 million from the Spanish Government via Centro para el Desarrollo Tecnologico e Innovacion (CDTI), $18 million from Kutxa Fundazioa, $12 million from the Basque Government and Ekarpen VC, and $2 million from BBK, alongside other Spanish and international private investors.
Related reading
- Samsung and AMD sign memory partnership deal to power next generation of AI chips
- WhatsApp adds storage, transfer and AI tools
- AI data centres can now dial down their power use in seconds
Dr. Laureano Simon, CEO of ONCOMATRYX, said: “We are thrilled to count on the continued support of our existing investors,” and added, “This funding validates the clinical progress of our lead candidate OMTX705 and equips us to take OMTX105 and other Quantum ADCs into clinical trials.” Kutxa Fundazioa also said its commitment increases its stake from 1.7% to 7.4%.
ONCOMATRYX develops ADCs that target Cancer‑Associated Fibroblasts in the tumor microenvironment. The company uses artificial intelligence (AI) tools and Quantum Computing to aid ADC design and candidate selection, and it is building an ADC Fill & Finish facility in San Sebastián. The announcement said Phase Ib–II clinical results for OMTX705 will be presented at major oncology conferences throughout 2026; the program is listed on ClinicalTrials.gov as NCT05547321.
The recap
- ONCOMATRYX raised $67 million to advance Quantum ADC candidates.
- Public and private investors contributed, including $28 million from CDTI.
- OMTX705 is the lead candidate; results will be presented throughout 2026.
